{
    "clinical_study": {
        "@rank": "134373", 
        "arm_group": [
            {
                "arm_group_label": "Calcium Phosphate stone formers without hypercalciuria", 
                "arm_group_type": "Placebo Comparator", 
                "description": "In this double-blind, placebo-controlled, crossover study, each subject will undergo 3 phases, the order of which will be randomized by a simple randomization scheme. The 3 phases will be Placebo, Citric Acid, and Potassium Citrate. Each phase will be 1 week in duration, during which subjects will take assigned study medications. A 1-week washout period is imposed between phases."
            }, 
            {
                "arm_group_label": "Calcium Phosphate stone formers with hypercalciuria", 
                "arm_group_type": "Placebo Comparator", 
                "description": "In this double-blind, placebo-controlled crossover study, each hypercalciuric CaP stone former will undergo 3 phases, the order of which will be randomized by a simple randomization scheme."
            }
        ], 
        "brief_summary": {
            "textblock": "The investigators will examine in two studies whether citric acid or potassium citrate can\n      reduce calcium phosphate saturation in urine of Calcium Phosphate stone formers."
        }, 
        "brief_title": "Treatment for Calcium Phosphate Kidney Stone Disease", 
        "completion_date": {
            "#text": "July 2014", 
            "@type": "Anticipated"
        }, 
        "condition": "Calcium Phosphate Kidney Stones", 
        "condition_browse": {
            "mesh_term": [
                "Calculi", 
                "Kidney Calculi", 
                "Nephrolithiasis", 
                "Urolithiasis"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n        Aim 1\n\n          -  Hypocitraturic CaP stone formers\n\n          -  urine citrate <320mg/d\n\n          -  elevated pH as 24-hr urine pH above 6.40\n\n          -  >21 years\n\n        Aim 2\n\n          -  Hypercalciuric CaP stone formers\n\n          -  24hr urine calcium >250mg/d in women and >300mg/d in men prior to indapamide use\n\n          -  high pH as >6.40 in the absence of urinary tract infection\n\n          -  >21 years"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "21 Years"
        }, 
        "enrollment": {
            "#text": "50", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "December 14, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01754779", 
            "org_study_id": "032012-058", 
            "secondary_id": "R21DK097476-01"
        }, 
        "intervention": [
            {
                "arm_group_label": [
                    "Calcium Phosphate stone formers without hypercalciuria", 
                    "Calcium Phosphate stone formers with hypercalciuria"
                ], 
                "description": "Matching placebo for both aims.", 
                "intervention_name": "Placebo", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": [
                    "Calcium Phosphate stone formers without hypercalciuria", 
                    "Calcium Phosphate stone formers with hypercalciuria"
                ], 
                "intervention_name": "Citric Acid", 
                "intervention_type": "Dietary Supplement"
            }, 
            {
                "arm_group_label": [
                    "Calcium Phosphate stone formers without hypercalciuria", 
                    "Calcium Phosphate stone formers with hypercalciuria"
                ], 
                "intervention_name": "Potassium Citrate", 
                "intervention_type": "Dietary Supplement"
            }, 
            {
                "arm_group_label": "Calcium Phosphate stone formers with hypercalciuria", 
                "description": "Aim 2", 
                "intervention_name": "Indapamide", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Calcium, Dietary", 
                "Citric Acid", 
                "Indapamide", 
                "Potassium Citrate"
            ]
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "calcium phosphate", 
            "urolithiasis", 
            "kidney stones", 
            "hypercalciuria"
        ], 
        "lastchanged_date": "December 18, 2012", 
        "location": {
            "contact": {
                "last_name": "Naim M Maalouf, MD"
            }, 
            "facility": {
                "address": {
                    "city": "Dallas", 
                    "country": "United States", 
                    "state": "Texas", 
                    "zip": "75390-8885"
                }, 
                "name": "UT Southwestern Medical Center"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "2", 
        "official_title": "Pharmacological Therapy for Calcium Phosphate Urolithiasis", 
        "overall_contact": {
            "email": "Reena.John@utsouthwestern.edu", 
            "last_name": "Reena John, RN", 
            "phone": "214-648-0399"
        }, 
        "overall_official": {
            "affiliation": "UT Southwestern Medical Center", 
            "last_name": "Naim M Maalouf, MD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": [
                "United States: Federal Government", 
                "United States: Institutional Review Board", 
                "United States: Food and Drug Administration"
            ], 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "July 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "Urinary calcium phosphate saturation", 
            "safety_issue": "No", 
            "time_frame": "2 weeks"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01754779"
        }, 
        "responsible_party": {
            "investigator_affiliation": "University of Texas Southwestern Medical Center", 
            "investigator_full_name": "Naim Maalouf", 
            "investigator_title": "Assistant Professor of Medicine", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "source": "University of Texas Southwestern Medical Center", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "University of Texas Southwestern Medical Center", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "July 2012", 
        "study_design": "Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "December 2012"
    }
}